PL4164595T3 - Kompozycje proszku anatabiny - Google Patents

Kompozycje proszku anatabiny

Info

Publication number
PL4164595T3
PL4164595T3 PL21730990.5T PL21730990T PL4164595T3 PL 4164595 T3 PL4164595 T3 PL 4164595T3 PL 21730990 T PL21730990 T PL 21730990T PL 4164595 T3 PL4164595 T3 PL 4164595T3
Authority
PL
Poland
Prior art keywords
anatabine
powder compositions
compositions
powder
anatabine powder
Prior art date
Application number
PL21730990.5T
Other languages
English (en)
Inventor
Fabiana SPADARO
Gérard ZUBER
Original Assignee
Philip Morris Products S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philip Morris Products S.A. filed Critical Philip Morris Products S.A.
Publication of PL4164595T3 publication Critical patent/PL4164595T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
PL21730990.5T 2020-06-15 2021-05-28 Kompozycje proszku anatabiny PL4164595T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20180100 2020-06-15
PCT/IB2021/054692 WO2021255560A1 (en) 2020-06-15 2021-05-28 Anatabine powder compositions

Publications (1)

Publication Number Publication Date
PL4164595T3 true PL4164595T3 (pl) 2025-11-24

Family

ID=71096637

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21730990.5T PL4164595T3 (pl) 2020-06-15 2021-05-28 Kompozycje proszku anatabiny

Country Status (11)

Country Link
US (1) US20230233459A1 (pl)
EP (1) EP4164595B1 (pl)
JP (1) JP2023529411A (pl)
KR (1) KR20230024889A (pl)
CN (1) CN115697299A (pl)
BR (1) BR112022022858A2 (pl)
CA (1) CA3170742A1 (pl)
ES (1) ES3040112T3 (pl)
MX (1) MX2022015578A (pl)
PL (1) PL4164595T3 (pl)
WO (1) WO2021255560A1 (pl)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6595210B2 (en) * 2000-11-27 2003-07-22 Unisia Jecs Corporation Inhalator for administering powder composition
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
CA2963423C (en) * 2007-03-30 2020-07-28 Philip Morris Products S.A. Device and method for delivery of a medicament
US8207346B2 (en) 2010-03-23 2012-06-26 Rock Creek Pharmaceuticals, Inc. Methods of synthesizing anatabine
EP3871674B1 (en) 2010-03-23 2024-12-25 Philip Morris Products S.A. Use of anatabine for reducing blood serum levels of c-reactive protein in an individual
US20130298921A1 (en) * 2011-06-23 2013-11-14 Rock Creek Pharmaceuticals, Inc. Inhaler for smoking cessation
CN108578405A (zh) 2011-08-29 2018-09-28 菲利普莫里斯产品有限公司 用于抗炎支持的产品
WO2015009500A1 (en) * 2013-07-19 2015-01-22 Williams Jonnie R Volatilized delivery of anatabine for treatment of substance addiction
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
CN109310623B (zh) * 2016-06-30 2022-10-21 菲利普莫里斯生产公司 尼古丁颗粒
EP3478264B1 (en) * 2016-06-30 2025-11-19 Philip Morris Products S.A. Nicotine particles and compositions
US11744962B2 (en) * 2018-03-26 2023-09-05 Philip Morris Products S.A. Inhaler with composite porous support element

Also Published As

Publication number Publication date
EP4164595A1 (en) 2023-04-19
EP4164595B1 (en) 2025-08-20
MX2022015578A (es) 2023-01-24
WO2021255560A1 (en) 2021-12-23
JP2023529411A (ja) 2023-07-10
CA3170742A1 (en) 2021-12-23
EP4164595C0 (en) 2025-08-20
US20230233459A1 (en) 2023-07-27
BR112022022858A2 (pt) 2022-12-20
KR20230024889A (ko) 2023-02-21
ES3040112T3 (en) 2025-10-28
CN115697299A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
GB201917917D0 (en) Tobacco composition
GB202013432D0 (en) Compositions
ZA202403158B (en) Compositions
PL4065661T3 (pl) Kompozycje
GB202015836D0 (en) Compositions
GB202105461D0 (en) Compositions
GB202102704D0 (en) Compositions
EP3959988A4 (en) POWDER COMPOSITION
GB2610026B (en) Compositions
GB202117953D0 (en) Aerosol-generating compositions
EP4282826A4 (en) POWDER COMPOSITION
IL315870A (en) The compounds containing cannabinoids
GB202014921D0 (en) Tobacco compositions and preparation thereof
GB202002048D0 (en) Compositions
EP4164595C0 (en) ANATABINE POWDER COMPOSITIONS
GB202307490D0 (en) Powder composition
GB202215776D0 (en) Powder composition
ZA202210764B (en) Compositions
GB202118081D0 (en) Compositions
GB202117074D0 (en) Compositions
GB202116861D0 (en) Compositions
GB202116387D0 (en) Compositions
GB202116388D0 (en) Compositions
GB202116386D0 (en) Compositions
GB202115617D0 (en) Compositions